{"name":"XOMA (US) LLC","slug":"xoma-us-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPTWdkLXZqTVBOSkpkbFA0WHcyVzNqT0NVcTExN0ZsaDQxMnUxaHE2SDlRZUZ0UW04NWlhSkdCNDZWaEtoVzlrWnpGRi1hYUpQNzJlQnkyOUdXVlFEaDk2dlVfczVibXVHRXRaZTBERzdUMGl4MDBFVHZlNm1aTmQtck51aFdXYmlRdm5SOVFWdUJabjFwVnVpWGpWQnRldw?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight - openPR.com","headline":"Acne Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2032, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPN1VTM09nTUl5QjlrN21hV0RLTVZ2dUQ3bnVGV1J3ZGphazJrNERqMXVoVEtnQjBISXFnaTgzTDZUcUI0Z2JidERRM2QwZVB2VG5BTmVHRWNGN3lGSjRQS3Y4TWhseGFOYllCODJEV3RGZ2s3RkU3VGtYWEQ3QVUxUjFMVVV4NDZpcmVISWlPOTd3aWhrYnlJN0F0OXFOUG9ZbzZxcXJYdVgyVUtzbjg4?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan","headline":"Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"earnings","source":"simplywall.st","summary":"XOMA Royalty (XOMA) Trailing Profitability Turnaround Challenges Skeptical Earnings Narratives - simplywall.st","headline":"XOMA Royalty (XOMA) Trailing Profitability Turnaround Challenges Skeptical Earnings Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbENZU3BnVGVQa3ZiQ0RhR3puWlpvaUJqcE9pOC0zay1yX29mNGtwNVBJQzdzSnlhaXhWelYzVVpMc2VLeFBvWkVPR2VuNUNHX1UtREp0VEZVY1RDRVIxdGlzU1ZwZlRIRVFPWWFHTS1vZEhVMGxWOVpBWnlwdFY4SThTOEowQ1llNTBwMEozR3hmYXdPZlJsNg?oc=5","date":"2026-03-11","type":"pipeline","source":"openPR.com","summary":"Acne Vulgaris Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Acne Vulgaris Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-03","type":"pipeline","source":"simplywall.st","summary":"XOMA Royalty Corporation (NASDAQ:XOMA) On The Verge Of Breaking Even - simplywall.st","headline":"XOMA Royalty Corporation (NASDAQ:XOMA) On The Verge Of Breaking Even","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-16","type":"pipeline","source":"simplywall.st","summary":"XOMA Royalty (NASDAQ:XOMA) Is Making Moderate Use Of Debt - simplywall.st","headline":"XOMA Royalty (NASDAQ:XOMA) Is Making Moderate Use Of Debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNWHpxM0ZLMW1UX3pVZEVpOEl1cnBxc0F3LWZVMXZ6Y1FJM3lhbVZPMG5GdzBwTDFjaExfTXloRDh2MzZxTjBTN1hsbkY5N3p3X1RNUFFOWkdESHVYcy04S0VFamZsRHFWa0lsYUY2YnB0Qi1WTWd3d1dXaTZESlhHZXRCek9VLXFSUkZ1RWt3ZGY?oc=5","date":"2024-04-03","type":"earnings","source":"Fierce Biotech","summary":"Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24 - Fierce Biotech","headline":"Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQLUlnYkpXSTE0Wks0T1BQSFFpdTNMdnNKNGdpbjFzODZheTNENjEtME9FQm4yY1B4d2dyelpIb0dPRGxSSnBwQl9KdlJxNkVXTVdPT09nY0IzV3QyS0ctZUtvQzBGUHNGd2NfRVlyNGo5RDZSN256dW9ZMmVMQWtEZWVCSnU1RFk5NDh5cTc3OXU3bV9yWU1lLUFMUUZHS1k1RjNVdV9SVFl6QQ?oc=5","date":"2018-04-19","type":"pipeline","source":"BioSpectrum Asia","summary":"Dr Michael Pugsley joins Veritas Pharma's Advisory Board - BioSpectrum Asia","headline":"Dr Michael Pugsley joins Veritas Pharma's Advisory Board","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}